Brandon M Triplett
Overview
Explore the profile of Brandon M Triplett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
752
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zandaki D, Selukar S, Bi Y, Li Y, Zinsky M, Bonifant C, et al.
Blood Adv
. 2024 Sep;
9(2):270-279.
PMID: 39325974
Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are complications of CD19-directed chimeric antigen receptor (CD19-CAR) T-cell therapy. The Endothelial Activation and Stress Index (EASIX) and modified...
2.
Kang M, Sharma R, Blanco C, Wiedeman D, Altemose Q, Lynch P, et al.
Sci Rep
. 2024 Aug;
14(1):18151.
PMID: 39103371
Ge-Sb-Se-Te chalcogenides, namely Se-substituted Ge-Sb-Te, have been developed as an alternative optical phase change material (PCM) with a high figure-of-merit. A need for the integration of such new PCMs onto...
3.
Moody J, Barker P, Sciasci J, Pauley J, Bragg A, McMillan C, et al.
Pediatr Blood Cancer
. 2024 Jul;
71(10):e31223.
PMID: 39054702
Blinatumomab is a bispecific T-cell engager administered as a 28-day continuous infusion. Infusions can be associated with interruptions requiring support from clinical staff, but the frequency of interventions with outpatient...
4.
Naik S, Li Y, Talleur A, Selukar S, Ashcraft E, Cheng C, et al.
J Hematol Oncol
. 2024 Jun;
17(1):50.
PMID: 38937803
Background: Relapse remains a challenge after transplantation in pediatric patients with hematological malignancies. Myeloablative regimens used for disease control are associated with acute and long-term adverse effects. We used a...
5.
Sharma A, Triplett B, Chi L, Cross S, Zheng Y, Arnold P
Hum Immunol
. 2024 Jun;
85(4):110829.
PMID: 38824859
A pediatric patient with acute myeloid leukemia was referred to our institution for investigational therapy after disease relapse following a mismatched unrelated donor hematopoietic cell transplant (HCT). Prior to second...
6.
Petgrave Y, Selukar S, Epperly R, Naik S, Santos N, Triplett B, et al.
Pediatr Nephrol
. 2024 Mar;
39(8):2495-2503.
PMID: 38507119
Background: CD19-specific chimeric antigen receptor (CAR) T-cell therapy has shown promising disease responses in patients with high-risk B-cell malignancies. However, its use may be related to complications such as immune-mediated...
7.
Zhou Y, Smith J, Keerthi D, Li C, Sun Y, Mothi S, et al.
Blood Adv
. 2023 Nov;
8(3):686-698.
PMID: 37991991
Serial prognostic evaluation after allogeneic hematopoietic cell transplantation (allo-HCT) might help identify patients at high risk of lethal organ dysfunction. Current prediction algorithms based on models that do not incorporate...
8.
Petgrave Y, Selukar S, Epperly R, Naik S, Santos N, Triplett B, et al.
Res Sq
. 2023 Oct;
PMID: 37886451
CD19-specific chimeric antigen receptor (CAR) T-cell therapy has shown promising disease responses in patients with high-risk B-cell malignancies. Treatment with CD19-CAR T-cell therapy is also associated with the risk of...
9.
Epperly R, Shulkin B, Bag A, Cheng C, Inaba H, Lucas J, et al.
Blood Adv
. 2023 Aug;
7(20):6320-6324.
PMID: 37595052
No abstract available.
10.
Margolis E, Alfaro G, Sun Y, Dallas R, Allison K, Ferrolino J, et al.
J Infect Dis
. 2023 May;
228(5):627-636.
PMID: 37249910
Background: Despite preventive measures, infections continue to pose significant risks to pediatric allogeneic hematopoietic cell transplantation (allo-HCT) recipients. The gut microbiota has been linked to clinical outcomes following adult allo-HCT....